Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms

The term lower urinary tract symptoms (LUTS) encompasses a range of urinary symptoms, including storage symptoms (e.g. overactive bladder [OAB]) as well as voiding and post‐micturition symptoms. Although treatment of male LUTS tends to focus on voiding symptoms, patients typically find storage sympt...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BJU international 2014-05, Vol.113 (5), p.696-703
Hauptverfasser: Chapple, Christopher R., Drake, Marcus J., Van Kerrebroeck, Philip, Cardozo, Linda, Drogendijk, Ted, Klaver, Monique, Van Charldorp, Karin, Hakimi, Zalmai, Compion, Gerhard
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 703
container_issue 5
container_start_page 696
container_title BJU international
container_volume 113
creator Chapple, Christopher R.
Drake, Marcus J.
Van Kerrebroeck, Philip
Cardozo, Linda
Drogendijk, Ted
Klaver, Monique
Van Charldorp, Karin
Hakimi, Zalmai
Compion, Gerhard
description The term lower urinary tract symptoms (LUTS) encompasses a range of urinary symptoms, including storage symptoms (e.g. overactive bladder [OAB]) as well as voiding and post‐micturition symptoms. Although treatment of male LUTS tends to focus on voiding symptoms, patients typically find storage symptoms the most bothersome. The core storage symptom is urgency, which drives the other main storage symptoms of increased daytime frequency, nocturia and incontinence. Although several validated questionnaires have been widely used to study urgency, few measure the two important storage parameters, urgency and frequency, in a single assessment. The total urgency and frequency score (TUFS) is a new validated tool that captures both variables and is derived from the Patient Perception of Intensity of Urgency Scale, which has been validated in patients with OAB and LUTS. The TUFS was first validated in OAB in the phase IIa BLOSSOM study, which was designed to assess the efficacy and safety of mirabegron, a β3‐adrenoceptor agonist, in 260 patients. The responsiveness of the TUFS to treatment has been confirmed in a further three large‐scale randomized controlled trials of solifenacin in patients with OAB or LUTS. Changes in TUFS from baseline to end of treatment were consistent with changes in micturition diary variables in all four studies. Furthermore, the TUFS was significantly correlated with several health‐related quality‐of‐life variables in the phase III NEPTUNE study. Thus, the TUFS appears to be useful for assessing improvements in major storage symptoms (urgency and frequency) in clinical trials.
doi_str_mv 10.1111/bju.12555
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1515643444</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3270518041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3835-b3f535880662f335588bf0a65843817299bd513c67e9eeff67f7592f560596743</originalsourceid><addsrcrecordid>eNp10UtLxDAQAOAgirs-Dv4BCYigh12T5tH2qOKTBS8K3kqaTqRL26xJu9I_4O823V0VBHNJZvjITDIIHVEypWFd5PNuSiMhxBYaUy75hFPyuv19JqkcoT3v54SEhBS7aBTxmEYpjcfo89m2qsKde4NG91g1BTYO3rtV5LV1gJXHCtegfBcCa_6xZYPtEpzSbbkEnFeqKMCtjG-tU2-AK_sRMp0rG-V63A4U-75etLb2B2jHqMrD4WbfRy-3N8_X95PZ093D9eVsolnCxCRnRjCRJETKyDAmwjE3REmRcJbQOErTvBCUaRlDCmCMjE0s0sgISUQqY8720dn63oWzoXHfZnXpNVSVasB2PqOCCskZ5wM9-UPntnNN6G5QnDApaRLU-VppZ713YLKFK-vwwIySbBhOFoaTrYYT7PHmxi6vofiR39MI4HQDlNeqMk41uvS_LnwBjcVQ9GLtPsoK-v8rZlePL-vSXxkBpeA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1514036618</pqid></control><display><type>article</type><title>Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>Chapple, Christopher R. ; Drake, Marcus J. ; Van Kerrebroeck, Philip ; Cardozo, Linda ; Drogendijk, Ted ; Klaver, Monique ; Van Charldorp, Karin ; Hakimi, Zalmai ; Compion, Gerhard</creator><creatorcontrib>Chapple, Christopher R. ; Drake, Marcus J. ; Van Kerrebroeck, Philip ; Cardozo, Linda ; Drogendijk, Ted ; Klaver, Monique ; Van Charldorp, Karin ; Hakimi, Zalmai ; Compion, Gerhard</creatorcontrib><description>The term lower urinary tract symptoms (LUTS) encompasses a range of urinary symptoms, including storage symptoms (e.g. overactive bladder [OAB]) as well as voiding and post‐micturition symptoms. Although treatment of male LUTS tends to focus on voiding symptoms, patients typically find storage symptoms the most bothersome. The core storage symptom is urgency, which drives the other main storage symptoms of increased daytime frequency, nocturia and incontinence. Although several validated questionnaires have been widely used to study urgency, few measure the two important storage parameters, urgency and frequency, in a single assessment. The total urgency and frequency score (TUFS) is a new validated tool that captures both variables and is derived from the Patient Perception of Intensity of Urgency Scale, which has been validated in patients with OAB and LUTS. The TUFS was first validated in OAB in the phase IIa BLOSSOM study, which was designed to assess the efficacy and safety of mirabegron, a β3‐adrenoceptor agonist, in 260 patients. The responsiveness of the TUFS to treatment has been confirmed in a further three large‐scale randomized controlled trials of solifenacin in patients with OAB or LUTS. Changes in TUFS from baseline to end of treatment were consistent with changes in micturition diary variables in all four studies. Furthermore, the TUFS was significantly correlated with several health‐related quality‐of‐life variables in the phase III NEPTUNE study. Thus, the TUFS appears to be useful for assessing improvements in major storage symptoms (urgency and frequency) in clinical trials.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/bju.12555</identifier><identifier>PMID: 24712917</identifier><identifier>CODEN: BJINFO</identifier><language>eng</language><publisher>Oxford: Wiley-Blackwell</publisher><subject>Biological and medical sciences ; Drug therapy ; frequency ; Global Health ; Humans ; lower urinary tract symptoms ; Lower Urinary Tract Symptoms - diagnosis ; Lower Urinary Tract Symptoms - physiopathology ; Medical sciences ; Nephrology. Urinary tract diseases ; overactive bladder ; Prevalence ; Severity of Illness Index ; Surveys and Questionnaires ; total urgency and frequency score ; urgency ; Urinary Bladder, Overactive - diagnosis ; Urinary Bladder, Overactive - physiopathology ; Urinary incontinence ; Urinary system involvement in other diseases. Miscellaneous ; Urinary tract. Prostate gland ; Urination - physiology ; Urogenital system</subject><ispartof>BJU international, 2014-05, Vol.113 (5), p.696-703</ispartof><rights>2013 The Authors. BJU International © 2013 BJU International</rights><rights>2015 INIST-CNRS</rights><rights>2013 The Authors. BJU International © 2013 BJU International.</rights><rights>BJUI © 2014 BJU International</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3835-b3f535880662f335588bf0a65843817299bd513c67e9eeff67f7592f560596743</citedby><cites>FETCH-LOGICAL-c3835-b3f535880662f335588bf0a65843817299bd513c67e9eeff67f7592f560596743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbju.12555$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbju.12555$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=28351758$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24712917$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chapple, Christopher R.</creatorcontrib><creatorcontrib>Drake, Marcus J.</creatorcontrib><creatorcontrib>Van Kerrebroeck, Philip</creatorcontrib><creatorcontrib>Cardozo, Linda</creatorcontrib><creatorcontrib>Drogendijk, Ted</creatorcontrib><creatorcontrib>Klaver, Monique</creatorcontrib><creatorcontrib>Van Charldorp, Karin</creatorcontrib><creatorcontrib>Hakimi, Zalmai</creatorcontrib><creatorcontrib>Compion, Gerhard</creatorcontrib><title>Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>The term lower urinary tract symptoms (LUTS) encompasses a range of urinary symptoms, including storage symptoms (e.g. overactive bladder [OAB]) as well as voiding and post‐micturition symptoms. Although treatment of male LUTS tends to focus on voiding symptoms, patients typically find storage symptoms the most bothersome. The core storage symptom is urgency, which drives the other main storage symptoms of increased daytime frequency, nocturia and incontinence. Although several validated questionnaires have been widely used to study urgency, few measure the two important storage parameters, urgency and frequency, in a single assessment. The total urgency and frequency score (TUFS) is a new validated tool that captures both variables and is derived from the Patient Perception of Intensity of Urgency Scale, which has been validated in patients with OAB and LUTS. The TUFS was first validated in OAB in the phase IIa BLOSSOM study, which was designed to assess the efficacy and safety of mirabegron, a β3‐adrenoceptor agonist, in 260 patients. The responsiveness of the TUFS to treatment has been confirmed in a further three large‐scale randomized controlled trials of solifenacin in patients with OAB or LUTS. Changes in TUFS from baseline to end of treatment were consistent with changes in micturition diary variables in all four studies. Furthermore, the TUFS was significantly correlated with several health‐related quality‐of‐life variables in the phase III NEPTUNE study. Thus, the TUFS appears to be useful for assessing improvements in major storage symptoms (urgency and frequency) in clinical trials.</description><subject>Biological and medical sciences</subject><subject>Drug therapy</subject><subject>frequency</subject><subject>Global Health</subject><subject>Humans</subject><subject>lower urinary tract symptoms</subject><subject>Lower Urinary Tract Symptoms - diagnosis</subject><subject>Lower Urinary Tract Symptoms - physiopathology</subject><subject>Medical sciences</subject><subject>Nephrology. Urinary tract diseases</subject><subject>overactive bladder</subject><subject>Prevalence</subject><subject>Severity of Illness Index</subject><subject>Surveys and Questionnaires</subject><subject>total urgency and frequency score</subject><subject>urgency</subject><subject>Urinary Bladder, Overactive - diagnosis</subject><subject>Urinary Bladder, Overactive - physiopathology</subject><subject>Urinary incontinence</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><subject>Urinary tract. Prostate gland</subject><subject>Urination - physiology</subject><subject>Urogenital system</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10UtLxDAQAOAgirs-Dv4BCYigh12T5tH2qOKTBS8K3kqaTqRL26xJu9I_4O823V0VBHNJZvjITDIIHVEypWFd5PNuSiMhxBYaUy75hFPyuv19JqkcoT3v54SEhBS7aBTxmEYpjcfo89m2qsKde4NG91g1BTYO3rtV5LV1gJXHCtegfBcCa_6xZYPtEpzSbbkEnFeqKMCtjG-tU2-AK_sRMp0rG-V63A4U-75etLb2B2jHqMrD4WbfRy-3N8_X95PZ093D9eVsolnCxCRnRjCRJETKyDAmwjE3REmRcJbQOErTvBCUaRlDCmCMjE0s0sgISUQqY8720dn63oWzoXHfZnXpNVSVasB2PqOCCskZ5wM9-UPntnNN6G5QnDApaRLU-VppZ713YLKFK-vwwIySbBhOFoaTrYYT7PHmxi6vofiR39MI4HQDlNeqMk41uvS_LnwBjcVQ9GLtPsoK-v8rZlePL-vSXxkBpeA</recordid><startdate>201405</startdate><enddate>201405</enddate><creator>Chapple, Christopher R.</creator><creator>Drake, Marcus J.</creator><creator>Van Kerrebroeck, Philip</creator><creator>Cardozo, Linda</creator><creator>Drogendijk, Ted</creator><creator>Klaver, Monique</creator><creator>Van Charldorp, Karin</creator><creator>Hakimi, Zalmai</creator><creator>Compion, Gerhard</creator><general>Wiley-Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>201405</creationdate><title>Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms</title><author>Chapple, Christopher R. ; Drake, Marcus J. ; Van Kerrebroeck, Philip ; Cardozo, Linda ; Drogendijk, Ted ; Klaver, Monique ; Van Charldorp, Karin ; Hakimi, Zalmai ; Compion, Gerhard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3835-b3f535880662f335588bf0a65843817299bd513c67e9eeff67f7592f560596743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Biological and medical sciences</topic><topic>Drug therapy</topic><topic>frequency</topic><topic>Global Health</topic><topic>Humans</topic><topic>lower urinary tract symptoms</topic><topic>Lower Urinary Tract Symptoms - diagnosis</topic><topic>Lower Urinary Tract Symptoms - physiopathology</topic><topic>Medical sciences</topic><topic>Nephrology. Urinary tract diseases</topic><topic>overactive bladder</topic><topic>Prevalence</topic><topic>Severity of Illness Index</topic><topic>Surveys and Questionnaires</topic><topic>total urgency and frequency score</topic><topic>urgency</topic><topic>Urinary Bladder, Overactive - diagnosis</topic><topic>Urinary Bladder, Overactive - physiopathology</topic><topic>Urinary incontinence</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><topic>Urinary tract. Prostate gland</topic><topic>Urination - physiology</topic><topic>Urogenital system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chapple, Christopher R.</creatorcontrib><creatorcontrib>Drake, Marcus J.</creatorcontrib><creatorcontrib>Van Kerrebroeck, Philip</creatorcontrib><creatorcontrib>Cardozo, Linda</creatorcontrib><creatorcontrib>Drogendijk, Ted</creatorcontrib><creatorcontrib>Klaver, Monique</creatorcontrib><creatorcontrib>Van Charldorp, Karin</creatorcontrib><creatorcontrib>Hakimi, Zalmai</creatorcontrib><creatorcontrib>Compion, Gerhard</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chapple, Christopher R.</au><au>Drake, Marcus J.</au><au>Van Kerrebroeck, Philip</au><au>Cardozo, Linda</au><au>Drogendijk, Ted</au><au>Klaver, Monique</au><au>Van Charldorp, Karin</au><au>Hakimi, Zalmai</au><au>Compion, Gerhard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2014-05</date><risdate>2014</risdate><volume>113</volume><issue>5</issue><spage>696</spage><epage>703</epage><pages>696-703</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><coden>BJINFO</coden><abstract>The term lower urinary tract symptoms (LUTS) encompasses a range of urinary symptoms, including storage symptoms (e.g. overactive bladder [OAB]) as well as voiding and post‐micturition symptoms. Although treatment of male LUTS tends to focus on voiding symptoms, patients typically find storage symptoms the most bothersome. The core storage symptom is urgency, which drives the other main storage symptoms of increased daytime frequency, nocturia and incontinence. Although several validated questionnaires have been widely used to study urgency, few measure the two important storage parameters, urgency and frequency, in a single assessment. The total urgency and frequency score (TUFS) is a new validated tool that captures both variables and is derived from the Patient Perception of Intensity of Urgency Scale, which has been validated in patients with OAB and LUTS. The TUFS was first validated in OAB in the phase IIa BLOSSOM study, which was designed to assess the efficacy and safety of mirabegron, a β3‐adrenoceptor agonist, in 260 patients. The responsiveness of the TUFS to treatment has been confirmed in a further three large‐scale randomized controlled trials of solifenacin in patients with OAB or LUTS. Changes in TUFS from baseline to end of treatment were consistent with changes in micturition diary variables in all four studies. Furthermore, the TUFS was significantly correlated with several health‐related quality‐of‐life variables in the phase III NEPTUNE study. Thus, the TUFS appears to be useful for assessing improvements in major storage symptoms (urgency and frequency) in clinical trials.</abstract><cop>Oxford</cop><pub>Wiley-Blackwell</pub><pmid>24712917</pmid><doi>10.1111/bju.12555</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1464-4096
ispartof BJU international, 2014-05, Vol.113 (5), p.696-703
issn 1464-4096
1464-410X
language eng
recordid cdi_proquest_miscellaneous_1515643444
source MEDLINE; Wiley Online Library
subjects Biological and medical sciences
Drug therapy
frequency
Global Health
Humans
lower urinary tract symptoms
Lower Urinary Tract Symptoms - diagnosis
Lower Urinary Tract Symptoms - physiopathology
Medical sciences
Nephrology. Urinary tract diseases
overactive bladder
Prevalence
Severity of Illness Index
Surveys and Questionnaires
total urgency and frequency score
urgency
Urinary Bladder, Overactive - diagnosis
Urinary Bladder, Overactive - physiopathology
Urinary incontinence
Urinary system involvement in other diseases. Miscellaneous
Urinary tract. Prostate gland
Urination - physiology
Urogenital system
title Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T08%3A37%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Total%20urgency%20and%20frequency%20score%20as%20a%20measure%20of%20urgency%20and%20frequency%20in%20overactive%20bladder%20and%20storage%20lower%20urinary%20tract%20symptoms&rft.jtitle=BJU%20international&rft.au=Chapple,%20Christopher%20R.&rft.date=2014-05&rft.volume=113&rft.issue=5&rft.spage=696&rft.epage=703&rft.pages=696-703&rft.issn=1464-4096&rft.eissn=1464-410X&rft.coden=BJINFO&rft_id=info:doi/10.1111/bju.12555&rft_dat=%3Cproquest_cross%3E3270518041%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1514036618&rft_id=info:pmid/24712917&rfr_iscdi=true